- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
- S-4 Registration of securities issued in business combination transactions
- 2.2 First Amendment to Merger Agreement, Dated As of February 9, 2022, by and Among Viveon Health Acquisition Corp., Vhac Merger Sub and Suneva Medical, Inc
- 10.19 Non-disclosure, Intellectual Property Protection and Non-solicitation Agreement for Suneva Medical, Inc
- 10.20 Form of Employment Agreement Between Suneva Medical, Inc. and Brian Pilcher
- 10.21 Form of Employment Agreement Between Suneva Medical, Inc. and Pamela Misajon
- 10.22 Form of Amended and Restated Employment Agreement Between Suneva Medical, Inc. and Patricia Altavilla
- 10.23 Suneva Medical, Inc. Offer Letter (Michael Brower) Dated February 15, 2022
- 10.24 Loan and Security Agreement Dated August 24, 2021, Between Suneva Medical, Inc. and Avenue Venture Opportunities Fund, LP
- 10.25 Supplement to Loan and Security Agreement Dated August 24, 2021 Between Suneva Medical, Inc. and Avenue Venture Opportunities Fund, LP
- 10.26 First Amendment to Loan Documents Dated May 10, 2022, Between Suneva Medical, Inc. and Avenue Venture Opportunities Fund, LP
- 10.27 Supply and Distribution Agreement Between Circa Skin and Suneva Medical
- 10.28 Distribution Agreement Between Neauvia and Suneva Medical
- 10.29 Quality Agreement Between Puregraft and Suneva Medical
- 10.30 Supply Agreement Between Merit Medical Systems and Suneva Medical
- 10.31 Supply and Distribution Agreement Between Sanwell Medical Equipment and Suneva Medical
- 10.32 Supply Agreement Between Healeon Medical and Suneva Medical
- 10.33 License Agreement Between Healeon Medical and Suneva Medical
- 10.34 Amendment to License Agreement Between Healeon Medical and Suneva Medical
- 10.35 Exclusive Distribution Agreement Between Aurastem Technologies and Suneva Medical
- 10.36 Distribution Agreement Between Sinclair Pharma Us and Suneva Medical
- 10.37 Amended and Restated Distribution and Supply Agreement Between Hangzhou ST. Nova Trade and Suneva Medical
- 10.38 Distribution and Supply Agreement Between Pacific Pharma and Suneva Medical
- 21.1 List of Subsidiaries
- 23.1 Consent of Marcum LLP, Independent Registered Public Accounting Firm of Viveon Health Acquisition Corp
- 23.2 Consent of Cohnreznick LLP, Independent Registered Public Accounting Firm of Suneva
- 99.1 Form of Preliminary Proxy Card
- 99.2 Consent of Patricia Altavilla to Be Named As a Director
- 99.3 Consent of Ron Eastman to Be Named As a Director
- 99.4 Consent of Jagi Gill to Be Named As a Director
- 99.5 Consent of Vince Ippolito to Be Named As a Director
- 99.6 Consent of Demetrios Logothetis to Be Named As a Director
- 99.7 Consent of Dennis Condon to Be Named As a Director
- 99.8 Consent of Brian Chee to Be Named As a Director
- EX-FILING FEES Filing Fee Table
- Download Excel data file
- View Excel data file
- 28 Feb 23 RW Registration withdrawal request
- 23 Nov 22 424B3 Prospectus supplement
- 17 Nov 22 424B3 Prospectus supplement
- 15 Nov 22 EFFECT Notice of effectiveness
- 10 Nov 22 S-4/A Registration of securities issued in business combination transactions (amended)
- 3 Nov 22 S-4/A Registration of securities issued in business combination transactions (amended)
- 19 Sep 22 S-4/A Registration of securities issued in business combination transactions (amended)
-
13 Jul 22 S-4 Registration of securities issued in business combination transactions
- 10 Nov 22 Registration of securities issued in business combination transactions (amended)
- 3 Nov 22 Registration of securities issued in business combination transactions (amended)
- 19 Sep 22 Registration of securities issued in business combination transactions (amended)
- 13 Jul 22 Registration of securities issued in business combination transactions
Exhibit 23.1
Independent Registered Public Accounting Firm’s Consent
We consent to the inclusion in this Registration Statement of Viveon Health Acquisition Corp. (the “Company”) on Form S-4 of our report dated March 31, 2022, which includes an explanatory paragraph as to the Company’s ability to continue as a going concern, with respect to our audits of the financial statements of the Company as of December 31, 2021 and 2020, and for the year ended December 31, 2021 and for the period from August 7, 2020 (inception) through December 31, 2020, which report appears in the Prospectus, which is part of this Registration Statement. We also consent to the reference to our Firm under the heading “Experts” in such Prospectus.
/s/ Marcum llp
Marcum llp
New York, NY
July 13, 2022